CancerNetwork Members: Login | Register
Become a fan on Facebook  Add us on Google Plus Follow us on Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 


 
PRACTICE GUIDELINES
Tumor Found in 42-Year-Old Patient During Hysterectomy
www.cancernetwork.com - 3/3/13
Cushing Syndrome
emedicine.medscape.com - 3/3/13
Retroperitoneal Fibrosis
emedicine.medscape.com - 2/25/13
 
CLINICAL TRIALS
Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
www.clinicaltrials.gov -
EPO906 in Carcinoid and Other Neuroendocrine Tumors
www.clinicaltrials.gov -
Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome
www.clinicaltrials.gov -
Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer
www.clinicaltrials.gov -
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
www.clinicaltrials.gov -

Result Pages: 1 2 3 4 5 6 Next


 
CONNECT WITH US
Become a fan on
Facebook
Add us on
Google Plus
Follow us on
Twitter
Join us on
LinkedIn
Sign up for our
Newsletters
Subscribe to our
RSS Feed

Carcinoid Tumors
 
FEATURED CONTENT
May 15, 2013
Anorexia and Cachexia
Many patients with advanced cancer undergo a wasting syndrome associated with cancer anorexia/cachexia and asthenia. In defining these terms a bit further, anorexia is associated with a marked loss of appetite and/or an aversion to food. More »
May 15, 2013
Carcinoma of an Unknown Primary Site
Carcinoma of an unknown primary site is a common clinical syndrome, accounting for approximately 3% of all oncologic diagnoses. Patients in this group are heterogeneous, having a wide variety of clinical presentations and pathologic findings. More »
April 26, 2013
A 47-Year-Old Patient With Chronic Abdominal Pain
A 47-year-old male with complaints of chronic abdominal pain and episodes of flushing presents for evaluation. What is your diagnosis? More »
March 8, 2013
Small-Cell Lung Cancer, Mesothelioma, and Thymoma
This management guide covers the symptoms, screening, diagnosis, and treatment of small-cell lung cancer (SCLC), mesothelioma, and thymoma from a surgical, medical, and radiation oncology approach. More »
March 8, 2013
Thyroid and Parathyroid Cancers
This management guide of endocrine malignancies covers the risk factors, diagnosis, screening, and treatment of both thyroid and parathyroid cancers. More »
Showing 1 - 5 of 121 results.
Page of 25
First Previous Last
 
JOURNAL SCAN
WJSO | Abstract | Association of carcinoid tumor and low grade glioma
www.wjso.com - 11/7/12
Lung carcinoid tumor and low grade glioma are two uncommon malignancies.|Lung carcinoid tumor and low grade glioma are two uncommon malignancies.
WJSO | Full text | Association of carcinoid tumor and low grade glioma
www.wjso.com - 11/7/12
Lung carcinoid tumor and low grade glioma are two uncommon malignancies.|Lung carcinoid tumor and low grade glioma are two uncommon malignancies.
Integrating targeted treatments with tumor biology and molecular imaging in the current and future management of neuroendocrine gastrointestinal tumors
annonc.oxfordjournals.org - 9/16/12

First recognized as "carcinoids" in the gastroenteropancreatic (GEP) tract, neuroendocrine tumors (NET) are a variety of neoplastic lesions distributed in most organs and apparata. The current World Health Organization (WHO 2010) define low and high grade neuroendocrine cancer types with the broad definition of neuroendocrine neoplasms and introduces grading (G1-G3) and Tumour Node Metastasis (TNM) staging for class definition. The proposed WHO 2010 grading system defines three classes (G1-G3) accordi

Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study
erc.endocrinology-journals.org - 9/13/12

Pasireotide (SOM230) is a novel multireceptor-targeted somatostatin (sst) analog with high binding affinity for sst receptor subtype 1, 2, 3 (sst1,2,3) and sst5. Because of this binding profile, pasireotide may offer symptom control in patients with neuroendocrine tumors (NETs) and carcinoid syndrome no longer responsive to octreotide LAR. This was a phase II, open-label, multicenter study of pasireotide in patients with advanced NET whose symptoms of carcinoid syndrome (diarrhea

PLOS ONE: Non-Covalent Interaction between Polyubiquitin and GTP Cyclohydrolase 1 Dictates Its Degradation
www.plosone.org - 9/11/12
PLOS ONE: an inclusive, peer-reviewed, open-access resource from the PUBLIC LIBRARY OF SCIENCE. Reports of well-performed scientific studies from all disciplines freely available to the whole world.

Result Pages: 1 2 3 4 5 6 Previous Next


 
MEDLINE
The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum.
pubmed.gov - 8/1/10
Well-differentiated neuroendocrine tumors (NETs) of the jejunum, ileum, and appendix are also collectively known as midgut carcinoids. Similar to NETs in general, the diagnosed incidence of the midgut NETs is on the rise. Their presenting symptoms vary depending on stage and primary site. Local-regional NETs often present with vague and nonspecific symptoms. Classic carcinoid syndrome is more likely to appear in patients with advanced disease. Local-regional NETs of the small bowel should be resected whenever possible. With the exception of small well-differentiated NETs of the appendix, NETs of the midgut have substantial risk of relapse after resection and need to be followed for at least 7 years.Metastatic/advanced NETs of the midgut are incurable. Optimal management requires a multidisciplinary approach. Somatostatin analogs are effective in the management of carcinoid syndrome. Octreotide long-acting release has also recently been shown to delay disease progression.
The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas.
pubmed.gov - 8/1/10
Extrapulmonary poorly differentiated neuroendocrine carcinomas can originate in the gastrointestinal tract, bladder, cervix, and prostate. These high-grade malignancies are characterized by aggressive histological features (high mitotic rate, extensive necrosis, and nuclear atypia) and a poor clinical prognosis. They are infrequently associated with secretory hormonal syndromes (such as the carcinoid syndrome) and rarely express somatostatin receptors.Most poorly differentiated neuroendocrine carcinomas are locally advanced or metastatic at presentation. First-line systemic chemotherapy with a platinum agent (cisplatin or carboplatin) and etoposide is recommended for most patients with metastatic-stage disease; however, response durations are often short. Sequential or concurrent chemoradiation is recommended for patients with loco-regional disease. In patients with localized tumors undergoing surgical resection, adjuvant treatment (chemotherapy with or without radiation) is warranted
Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis.
pubmed.gov - 12/12/04
Among new biological markers that could become useful prognostic factors for lung carcinoma, Ki-67 is a nuclear protein involved in cell proliferation regulation. Some studies have suggested an association between Ki-67 and poor survival in lung cancer patients. In order to clarify this point, we have performed a systematic review of the literature, using the methodology already described by our Group, the European Lung Cancer Working Party. In total, 37 studies, including 3983 patients, were found to be eligible. In total, 49% of the patients were considered as having a tumour positive for the expression of Ki-67 according to the authors cutoff. In all, 29 of the studies dealt with non-small-cell lung carcinoma (NSCLC), one with small-cell carcinoma (SCLC), two with carcinoid tumours and five with any histology. In terms of survival results, Ki-67 was a bad prognosis factor for survival in 15 studies while it was not in 22. As there was no statistical difference in quality scores
Gastric carcinoids: a statistical evaluation of 1,094 cases collected from the literature.
pubmed.gov - 1/1/97
Gastric carcinoids are a rare gut endocrinoma, and only a few series dealing with limited aspects have been published. This study evaluates the present status and characteristics of gastric carcinoids in a statistically reliable series of 1,094 cases that were carefully evaluated, computerized, and analyzed by the "Gut-Pancreatic Endocrinoma Analyzing System." Routine statistical analysis was carried out on 1,011 patients, excluding 83 with atypical carcinoids, focusing on clinical manifestations, location, depth, and size of the lesions in relation to metastases, immunohistochemistry, carcinoid syndrome, serotonin activity, electron microscopy, multicarcinoid complex with type A gastritis, and postoperative outcome. A tumor size of 20 mm or less comprised 60.8% of the series, with a metastasis rate of 15.1%, and depth of invasion to the submucosa occupied 53.8%, with a metastasis rate of 13.2%. Carcinoid syndrome was encountered in 4.0% of the patients. Elevated serotonin activity
Evidence for the existence of different types of large bowel tumor: suggestions from the clinical data of a population-based registry.
pubmed.gov - 5/1/90
The clinical findings of a population-based colorectal tumor registry have been analyzed to determine elements of supporting or not supporting the existence of different types of large bowel cancer. Age-specific incidence rate of the 409 registered patients rose sharply with increasing age in all segments of the large bowel; however, regarding left colon and rectum, the male: female ratio showed a marked male preponderance, more evident in the more advanced age groups. Histopathology, studied in 87% of patients, revealed adenocarcinoma as the most frequent feature; however, adenocarcinoma with concomitant adenoma (i.e., presumably arising in adenoma) was observed in 14.3% of cancers of the left colon, in 17.7% of rectal tumors, but in only 5.7% of neoplasms of the proximal colon (P less than 0.05 and P less than 0.01, respectively, vs. left colon and rectum). Some histological features (carcinoid and mucinous carcinoma) were observed in right-side tumors only. Analysis of the familial


 
TOPIC INDEX

Cancer Types

  

Supportive Care

More Topics


All Topics 


 
   SEARCH MEDICA RX
   Browse drugs by name:
A B C D E F G H I J
K L M N O P Q R S T
U V W X Y Z All      
   Search for drugs:
Search

 
 
FROM PHYSICIANS PRACTICE
Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice
Susanne Madden,  June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler,  June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate,  June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.
iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.